Oral Semaglutide vs. Sitagliptin: PIONEER 3 Study
Updated: Sep 8
Rosenstock J et al. conducted the PIONEER 3 trial to compare the effectiveness of oral Semaglutide against Sitagliptin in adult Type 2 diabetes patients who were not adequately controlled on Metformin alone or with sulfonylurea. This study robustly evaluated the impacts on HbA1c reduction and the changes in body weight from baseline (1).
Study Summary
About the Author
Ms. Silpa Rani Gajavalli is a postgraduate in pharmaceutical science (M Pharmacy). She has a wealth of academic experience and is passionate about Medical Writing. Silpa regularly posts articles on the latest advancements in medical research, pharmacological agents, clinical aspects of medicine, innovative treatments, regulatory aspects, and landmark clinical trials.
Abbreviations
T2DM: Type 2 diabetes mellitus; HbA1c: Haemoglobin A1c; MET: Metformin;
Reference
Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, et al; PIONEER 3 Investigators. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019. Apr 16;321(15):1466-1480.
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in
Comments